The global radioimmunoassay market was valued at US$ 433.9 Million in 2022 and is expected to reach US$ 690.8 Million by 2033. The clinical use segment with a market share more than 82.0% has topped the global market within the purpose category and is expected to grow at a CAGR of close to 3.8% over the forecast period (2023 to 2033)
Market Outlook:
| Data Points | Market Insights |
|---|---|
| Market Value 2022 | US$ 433.9 Million |
| Market Value 2023 | US$ 451.0 Million |
| Market Value 2033 | US$ 690.8 Million |
| CAGR 2023 to 2033 | 4.4% |
| Market Share of Top 5 Countries | 57.7% |
| Key Market Players | PerkinElmer Inc., Berthold Technologies GmbH & Co.KG, LKB Instruments, Montreal Biotech, DIAsource, Abbexa, IBL International GmbH, Creative Biolabs, MP BIOMEDICALS, ALPCO, Padyab Teb Co., Merck KGaA, NovoLytiX GmbH, Beckman Coulter, Inc., DiaSorin S.p.A., DRG INSTRUMENTS GMBH, and EUROIMMUN Medizinische Labordiagnostika AG. |
The foundation of radioimmunoassay (RIA) is the formation of antigen-antibody complexes as a result of the competition between labelled and unlabelled antigens for certain antibody sites. Radioimmunoassay is an extremely sensitive method for measuring antigen quantities without the use of a conventional bioassay. RIA is used to estimate the antigenicity of compounds, either naturally or through chemical modification. Hormones, tumour indicators (peptides, proteins, steroids, etc.), vitamins, medicines, and other substances all can be estimated by using this technique.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The historical market for radioimmunoassay was around 1.1% of the overall global immunoassay market US$ 40.2 Billion in 2022. Demographic factor as population size, age, distribution and disease prevalence can influence the RIA market. The aging population is more prone to diseases and needs diagnosis. Technological advancement in kit development can help to provide improved, automated and rapid diagnostic methods. These factors significantly shape the demand, adoption, and growth of the market on a global scale. It is essential for businesses operating in this market to closely monitor and understand these factors to make informed decisions and strategies.
Another major health-related issue is diabetes.
Somatostatin levels are measured using a radioimmunoassay (RIA) but require a longer duration for the development of results. Scientists have undertaken a task to transform the kit into a straightforward handheld gadget that can be mass-produced in a short period. These major applications of radioimmunoassay technology will boost demand for it globally.
The availability and quality of healthcare infrastructure, including hospitals, clinics, and diagnostic centers, can impact the adoption of radioimmunoassay. Regions with well-developed healthcare systems are more likely to embrace and integrate advanced medical technologies.
An opportunity exists for the radioimmunoassay industry due to the growth in cancer, chronic illnesses, infectious diseases, therapeutic drug monitoring, and drug addiction throughout the world as well as its use in the diagnosis of autoimmune diseases, cardiology, and endocrinology. This technology can aid in the early detection, monitoring, and management of these conditions, leading to improved patient outcomes.
Collaborations and partnerships between healthcare providers, research institutions, and technology companies can foster innovation and accelerate the adoption of radioimmunoassay. Joint efforts in research, development, and commercialization can lead to the expansion of market reach and the development of new applications.
This initiative has helped local RIA kits manufacturer to develop and promote their products within the country. This provides an opportunity for emerging and local manufacturers to expand in the market.
Principal Consultant
The market faces competition from alternative diagnostic technologies such as stable free radicals, fluorochromes, chemiluminescence precursors, enzyme inhibitors, and methods. These are easy to handle, can give qualitative and quantitative information and easy to discard post experiment.
This competition can limit market penetration and slow down the growth of radioimmunoassay, particularly in regions where other technologies are more established. It is largely restricted to immunoassays, the need for expensive reagents and equipment and the requirements for licensing and containment. Another important problem is disposal of radioactive waste management, special training and license required and expensive instrumentation.
The USA occupies 29.8% share in global RIA market in the year 2022. The USA has a significant burden of chronic diseases such as obesity, diabetes and cardiovascular diseases. Radioimmunoassay is used in the assessing and managing of these conditions, making it relevant and in demand within the USA healthcare system. The USA has a competitive medical device market, with various manufacturers and suppliers offering radioimmunoassay kit and related products. The demand for radioimmunoassay in the USA market is driven by the need for accurate and invasive diagnostic tools.
The Germany accounts for US$ 38.0 Million in the global market in 2022. Germany boasts a skilled and well-trained healthcare workforce, including physicians, researchers, and technicians. These professionals are knowledgeable in the use and interpretation of radioimmunoassay data, enabling widespread adoption and application of the technology in clinical practice and research. Prominent immunodiagnostic kit developing industries are located in Germany giving it an upper hand in market.
China held a dominant share of the East Asia market and contributed around US$ 35.8 Million in 2022. The country's swiftly expanding middle class has boosted expenditure on healthcare and disposable money. The need for better-quality healthcare goods, like radioimmunoassay, has increased as a result of demographic shifts. The rising middle class's increased disposable income has helped the Chinese economy expand. The Chinese population is second largest in world making it a huge market for disease diagnostics, RIA being able to identify high level of sensitivity is prominently used for diagnosis many china a large market for radioimmunoassay.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Kits & reagents accounted for US$ 262.9 Million, representing a sizable 60.2% global market share in 2022. The kits and reagents are inexpensive, simple to use, and readily available. They offer great specificity and selectivity, delivering thorough information on biomolecule diagnosis. The compounds are simple to produce and ship as kits, making them readily available. Reagent and kit manufacture takes less time; therefore, they are always ready when needed.
The infectious disease segment accounted for the predominant share in the global market, with a revenue share of 33.5% in 2022. Mutations in bacteria and viruses have increased the prevalence of infectious illnesses in recent years. Bacterial strains that are multi-drug resistant have rapidly developed, and viruses' pathogenicity has increased significantly in parallel. Infectious illness cases have increased as a result, necessitating an immediate and precise diagnosis. Since RIA makes this possible, the segment is the most profitable segment for radioimmunoassay market.
The hospitals have a considerable presence in the global market accounting for 27.4% market share in 2022 and expected to grow at a CAGR of 5.4%. When in pain, individuals with and without chronic or infectious disorders visit hospitals. Because nurses and doctors are well-trained and knowledgeable to handle and comprehend these procedures, hospitals are the most beneficial end user in the market.
The clinical use segment contributes US$ 356.6 Million globally in 2022. A significant number of RIA kits are the result of research and development, but their primary function is the detection and identification of a particular molecular target. A vast number of disorders are associated with variations in biomolecule levels. Based on the results of the initial screening, patients are then directed onto RIA, which provides thorough health information. The variety of radioimmunoassay are utilised for clinical purposes since once standardised, an assay does not require further study.
Serum accounted for US$ 179.6 Million market value in 2022. The sizeable amount of RIAs used to diagnose diseases are carried out on patient serum. Since the serum circulates throughout the body, it contains the most freely floating biomolecules that are present in a person. Serum is easily available, has high amount of antigen, and can be used for multiple test other than RIA, hence it is preferred over saliva, urine, plasma and cell culture sample.
The market for radioimmunoassay is fragmented in nature with numerous prominent firms competing in the market. Collaborations and agreements between healthcare providers, research institutions, and tech companies can spur innovation and speed up the spread of radioimmunoassay. Investment in research and development with commercialization of technologically improved products can lead to market expansion. Among the well-known players in this field are:
Similarly, recent developments related to the companies in the radioimmunoassay market have been tracked by the team at Future Market Insights, which are available in the full report.
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2012 to 2022 |
| Market Analysis | US$ Million for Value & Units for Volume |
| Key Regions Covered | North America, Latin America, Europe, East Asia, South Asia, Middle East and Africa (MEA) |
| Key Countries Covered | USA, Canada, Brazil, Mexico, Argentina, Germany, France, Spain, Russia, Italy, BENELUX, UK, India, Indonesia, Thailand, Philippines, Malaysia, Vietnam, China, Japan, South Korea, Australia, New Zealand, GCC countries, Türkiye, South Africa and Northern Africa. |
| Key Market Segments Covered | Product, Application, Purpose, Sample Type, End User, and Region |
| Key Companies Profiled |
|
| Report Coverage |
|
| Pricing | Available upon Request |
The market is estimated to secure a valuation of US$ 451.0 million in 2023.
The global market size is expected to reach US$ 690.8 million by 2033.
The growth potential of the market is 4.4% through 2033.
The market share of top five countries is 57.7%.
There are two types of RIA, including coated-tube RIA and double-antibody RIA.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply-Side Trends 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 2.3. Inclusions and Exclusions 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Product Innovation / Development Trends 4. Value-Added Insights 4.1. Product Adoption Analysis 4.2. Product USPs/Features Analysis 4.3. Regulatory Landscape, By Country 4.4. Disease Epidemiology, By Key Indication 4.5. Porter’s Analysis 4.6. PESTLE Analysis 4.7. Value Chain Analysis 4.8. Unmet Needs Analysis 5. Market Background 5.1. Macro-Economic Factors 5.1.1. Global Healthcare Expenditure Outlook 5.1.2. Global Life Science Market Outlook 5.1.3. Global Immunoassay Market Outlook 5.2. Forecast Factors - Relevance & Impact 5.2.1. Rising Cases of Chronic Illness 5.2.2. Increase in Research and Development 5.2.3. Government Initiative for Early Diagnosis 5.2.4. Growth of Clinical Diagnostics 5.2.5. Technological Advancements 5.2.6. Cost of Product 5.2.7. Adoption Rate 5.3. Market Dynamics 5.3.1. Drivers 5.3.2. Restraints 5.3.3. Opportunity Analysis 6. Global Market Demand Volume (Units) Analysis 2012 to 2022 and Forecast, 2023 to 2033 6.1. Historical Market Volume (Units) Analysis, 2012 to 2022 6.2. Current and Future Market Volume (Units) Analysis and Forecast Projections, 2023 to 2033 6.2.1. Y-o-Y Growth Trend Analysis 7. Global Market - Pricing Analysis 7.1. Regional Pricing Analysis By Product 7.2. Global Average Pricing Analysis Benchmark 7.3. Pricing Assumptions 8. Global Market Demand (in Value or Size in US$ Million) Analysis 2012 to 2022 and Forecast, 2023 to 2033 8.1. Historical Market Value (US$ Million) Analysis, 2012 to 2022 8.2. Current and Future Market Size (US$ Million) Analysis and Forecast Projections, 2023 to 2033 8.2.1. Y-o-Y Growth Trend Analysis 8.2.2. Absolute $ Opportunity Analysis 8.3. Revenue Opportunity Scenario- Likely/Conservative/Optimistic 9. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By Product 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ Million) and Volume (Units) By Product, 2012 to 2022 9.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Product, 2023 to 2033 9.3.1. Kits and Reagents 9.3.1.1. Kits 9.3.1.2. Antibodies 9.3.2. Instruments 9.3.3. Consumables 9.3.4. Services 9.4. Market Attractiveness Analysis By Product 10. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By Application 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Million) Analysis By Application, 2012 to 2022 10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Application, 2023 to 2033 10.3.1. Oncology 10.3.2. Cardiology 10.3.3. Endocrinology 10.3.4. Infectious Disease 10.3.5. Autoimmune Disease 10.3.6. Therapeutic Drug Monitoring 10.3.7. Drug of Abuse 10.3.8. Others 10.4. Market Attractiveness Analysis By Application 11. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By Purpose 11.1. Introduction / Key Findings 11.2. Historical Market Size (US$ Million) Analysis By Purpose, 2012 to 2022 11.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Purpose, 2023 to 2033 11.3.1. Research Use Only 11.3.2. Clinical Use 11.4. Market Attractiveness Analysis By Purpose 12. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By Sample Type 12.1. Introduction / Key Findings 12.2. Historical Market Size (US$ Million) Analysis By Sample Type, 2012 to 2022 12.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Sample Type, 2023 to 2033 12.3.1. Serum 12.3.2. Plasma 12.3.3. Urine 12.3.4. Saliva 12.3.5. Cell Culture Sample 12.4. Market Attractiveness Analysis By Sample Type 13. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, By End User 13.1. Introduction / Key Findings 13.2. Historical Market Size (US$ Million) Analysis By End User, 2012 to 2022 13.3. Current and Future Market Size (US$ Million) Analysis and Forecast By End User, 2023 to 2033 13.3.1. Hospital 13.3.2. Specialty Clinics 13.3.3. Academic and Research Institute 13.3.4. Diagnostics Laboratories 13.3.5. Reference Laboratories 13.3.6. Cancer Research Institutes 13.3.7. Veterinary Hospitals 13.4. Market Attractiveness Analysis By End User 14. Global Market Analysis 2012 to 2022 and Forecast 2023 to 2033, by Region 14.1. Introduction / Key Findings 14.2. Historical Market Size (US$ Million) and Volume (Units) Analysis By Region, 2012 to 2022 14.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis Forecast By Region, 2023 to 2033 14.3.1. North America 14.3.2. Latin America 14.3.3. Europe 14.3.4. South Asia 14.3.5. East Asia 14.3.6. Oceania 14.3.7. Middle East and Africa 14.4. Market Attractiveness Analysis By Region 15. North America Market Analysis 2012 to 2022 and Forecast 2023 to 2033 15.1. Introduction / Key Findings 15.2. Historical Market Size (US$ Million) and Volume (Units) Analysis, By Market Taxonomy, 2012 to 2022 15.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Market Taxonomy, 2023 to 2033 15.3.1. By Country 15.3.1.1. USA 15.3.1.2. Canada 15.3.2. By Product 15.3.3. By Application 15.3.4. By Purpose 15.3.5. By Sample Type 15.3.6. By End User 15.4. Market Attractiveness Analysis By Region 15.4.1. By Country 15.4.2. By Product 15.4.3. By Application 15.4.4. By Purpose 15.4.5. By Sample Type 15.4.6. By End User 15.5. Market trends 15.6. Key Market Participants - Intensity Mapping 15.7. Drivers and Restraints - Impact Analysis 15.8. Country Level Analysis & Forecast 15.8.1. USA Market Analysis 15.8.1.1. Introduction 15.8.1.2. Market Analysis and Forecast by Market Taxonomy 15.8.1.2.1. By Product 15.8.1.2.2. By Application 15.8.1.2.3. By Purpose 15.8.1.2.4. By Sample Type 15.8.1.2.5. By End User 15.8.2. Canada Market Analysis 15.8.2.1. Introduction 15.8.2.2. Market Analysis and Forecast by Market Taxonomy 15.8.2.2.1. By Product 15.8.2.2.2. By Application 15.8.2.2.3. By Purpose 15.8.2.2.4. By Sample Type 15.8.2.2.5. By End User 16. Latin America Market Analysis 2012 to 2022 and Forecast 2023 to 2033 16.1. Introduction / Key Findings 16.2. Historical Market Size (US$ Million) and Volume (Units) Analysis, By Market Taxonomy, 2012 to 2022 16.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Market Taxonomy, 2023 to 2033 16.3.1. By Country 16.3.1.1. Brazil 16.3.1.2. Mexico 16.3.1.3. Argentina 16.3.1.4. Rest of Latin America 16.3.2. By Product 16.3.3. By Application 16.3.4. By Purpose 16.3.5. By Sample Type 16.3.6. By End User 16.4. Market Attractiveness Analysis By Region 16.4.1. By Country 16.4.2. By Product 16.4.3. By Application 16.4.4. By Purpose 16.4.5. By Sample Type 16.4.6. By End User 16.5. Market trends 16.6. Key Market Participants - Intensity Mapping 16.7. Drivers and Restraints - Impact Analysis 16.8. Country Level Analysis & Forecast 16.8.1. Brazil Market Analysis 16.8.1.1. Introduction 16.8.1.2. Market Analysis and Forecast by Market Taxonomy 16.8.1.2.1. By Product 16.8.1.2.2. By Application 16.8.1.2.3. By Purpose 16.8.1.2.4. By Sample Type 16.8.1.2.5. By End User 16.8.2. Mexico Market Analysis 16.8.2.1. Introduction 16.8.2.2. Market Analysis and Forecast by Market Taxonomy 16.8.2.2.1. By Product 16.8.2.2.2. By Application 16.8.2.2.3. By Purpose 16.8.2.2.4. By Sample Type 16.8.2.2.5. By End User 16.8.3. Argentina Market Analysis 16.8.3.1. Introduction 16.8.3.2. Market Analysis and Forecast by Market Taxonomy 16.8.3.2.1. By Product 16.8.3.2.2. By Application 16.8.3.2.3. By Purpose 16.8.3.2.4. By Sample 16.8.3.2.5. Type By End User 17. Europe Market Analysis 2012 to 2022 and Forecast 2023 to 2033 17.1. Introduction / Key Findings 17.2. Historical Market Size (US$ Million) Volume (Units) Analysis, By Market Taxonomy, 2012 to 2022 17.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Market Taxonomy, 2023 to 2033 17.3.1. By Country 17.3.1.1. Germany 17.3.1.2. France 17.3.1.3. Spain 17.3.1.4. Russia 17.3.1.5. Italy 17.3.1.6. BENELUX 17.3.1.7. UK 17.3.1.8. Rest of Europe 17.3.2. By Product 17.3.3. By Application 17.3.4. By Purpose 17.3.5. By Sample Type 17.3.6. By End User 17.4. Market Attractiveness Analysis By Region 17.4.1. By Country 17.4.2. By Product 17.4.3. By Application 17.4.4. By Purpose 17.4.5. By Sample Type 17.4.6. By End User 17.5. Market trends 17.6. Key Market Participants - Intensity Mapping 17.7. Drivers and Restraints - Impact Analysis 17.8. Country Level Analysis & Forecast 17.8.1. Germany Market Analysis 17.8.1.1. Introduction 17.8.1.2. Market Analysis and Forecast by Market Taxonomy 17.8.1.2.1. By Product 17.8.1.2.2. By Application 17.8.1.2.3. By Purpose 17.8.1.2.4. By Sample Type 17.8.1.2.5. By End User 17.8.2. France Market Analysis 17.8.2.1. Introduction 17.8.2.2. Market Analysis and Forecast by Market Taxonomy 17.8.2.2.1. By Product 17.8.2.2.2. By Application 17.8.2.2.3. By Purpose 17.8.2.2.4. By Sample Type 17.8.2.2.5. By End User 17.8.3. Spain Market Analysis 17.8.3.1. Introduction 17.8.3.2. Market Analysis and Forecast by Market Taxonomy 17.8.3.2.1. By Product 17.8.3.2.2. By Application 17.8.3.2.3. By Purpose 17.8.3.2.4. By Sample 17.8.3.2.5. Type By End User 17.8.4. Russia Market Analysis 17.8.4.1. Introduction 17.8.4.2. Market Analysis and Forecast by Market Taxonomy 17.8.4.2.1. By Product 17.8.4.2.2. By Application 17.8.4.2.3. By Purpose 17.8.4.2.4. By Sample 17.8.4.2.5. Type By End User 17.8.5. Italy Market Analysis 17.8.5.1. Introduction 17.8.5.2. Market Analysis and Forecast by Market Taxonomy 17.8.5.2.1. By Product 17.8.5.2.2. By Application 17.8.5.2.3. By Purpose 17.8.5.2.4. By Sample Type 17.8.5.2.5. By End User 17.8.6. BENELUX Market Analysis 17.8.6.1. Introduction 17.8.6.2. Market Analysis and Forecast by Market Taxonomy 17.8.6.2.1. By Product 17.8.6.2.2. By Application 17.8.6.2.3. By Purpose 17.8.6.2.4. By Sample Type 17.8.6.2.5. By End User 17.8.7. UK Market Analysis 17.8.7.1. Introduction 17.8.7.2. Market Analysis and Forecast by Market Taxonomy 17.8.7.2.1. By Product 17.8.7.2.2. By Application 17.8.7.2.3. By Purpose 17.8.7.2.4. By Sample Type 17.8.7.2.5. By End User 18. South Asia Market Analysis 2012 to 2022 and Forecast 2023 to 2033 18.1. Introduction / Key Findings 18.2. Historical Market Size (US$ Million) Volume (Units) Analysis, By Market Taxonomy, 2012 to 2022 18.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Market Taxonomy, 2023 to 2033 18.3.1. By Country 18.3.1.1. India 18.3.1.2. Indonesia 18.3.1.3. Thailand 18.3.1.4. Philippines 18.3.1.5. Malaysia 18.3.1.6. Vietnam 18.3.1.7. Rest of South Asia 18.3.2. By Product 18.3.3. By Application 18.3.4. By Purpose 18.3.5. By Sample Type 18.3.6. By End User 18.4. Market Attractiveness Analysis By Region 18.4.1. By Country 18.4.2. By Product 18.4.3. By Application 18.4.4. By Purpose 18.4.5. By Sample Type 18.4.6. By End User 18.5. Market trends 18.6. Key Market Participants - Intensity Mapping 18.7. Drivers and Restraints - Impact Analysis 18.8. Country Level Analysis & Forecast 18.8.1. India Market Analysis 18.8.1.1. Introduction 18.8.1.2. Market Analysis and Forecast by Market Taxonomy 18.8.1.2.1. By Product 18.8.1.2.2. By Application 18.8.1.2.3. By Purpose 18.8.1.2.4. By Sample Type 18.8.1.2.5. By End User 18.8.2. Indonesia Market Analysis 18.8.2.1. Introduction 18.8.2.2. Market Analysis and Forecast by Market Taxonomy 18.8.2.2.1. By Product 18.8.2.2.2. By Application 18.8.2.2.3. By Purpose 18.8.2.2.4. By Sample Type 18.8.2.2.5. By End User 18.8.3. Thailand Market Analysis 18.8.3.1. Introduction 18.8.3.2. Market Analysis and Forecast by Market Taxonomy 18.8.3.2.1. By Product 18.8.3.2.2. By Application 18.8.3.2.3. By Purpose 18.8.3.2.4. By Sample Type 18.8.3.2.5. By End User 18.8.4. Philippines Market Analysis 18.8.4.1. Introduction 18.8.4.2. Market Analysis and Forecast by Market Taxonomy 18.8.4.2.1. By Product 18.8.4.2.2. By Application 18.8.4.2.3. By Purpose 18.8.4.2.4. By Sample Type 18.8.4.2.5. By End User 18.8.5. Malaysia Market Analysis 18.8.5.1. Introduction 18.8.5.2. Market Analysis and Forecast by Market Taxonomy 18.8.5.2.1. By Product 18.8.5.2.2. By Application 18.8.5.2.3. By Purpose 18.8.5.2.4. By Sample Type 18.8.5.2.5. By End User 18.8.6. Vietnam Market Analysis 18.8.6.1. Introduction 18.8.6.2. Market Analysis and Forecast by Market Taxonomy 18.8.6.2.1. By Product 18.8.6.2.2. By Application 18.8.6.2.3. By Purpose 18.8.6.2.4. By Sample Type 18.8.6.2.5. By End User 19. East Asia Market Analysis 2012 to 2022 and Forecast 2023 to 2033 19.1. Introduction / Key Findings 19.2. Historical Market Size (US$ Million) and Volume (Units) Analysis, By Market Taxonomy, 2012 to 2022 19.3. Current and Future Market Size (US$ Million) and Volume (Units) Analysis and Forecast By Market Taxonomy, 2023 to 2033 19.3.1. By Country 19.3.1.1. China 19.3.1.2. Japan 19.3.1.3. South Korea 19.3.2. By Product 19.3.3. By Application 19.3.4. By Purpose 19.3.5. By Sample Type 19.3.6. By End User 19.4. Market Attractiveness Analysis By Region 19.4.1. By Country 19.4.2. By Product 19.4.3. By Application 19.4.4. By Purpose 19.4.5. By Sample Type 19.4.6. By End User 19.5. Market trends 19.6. Key Market Participants - Intensity Mapping 19.7. Drivers and Restraints - Impact Analysis 19.8. Country Level Analysis & Forecast 19.8.1. China Market Analysis 19.8.1.1. Introduction 19.8.1.2. Market Analysis and Forecast by Market Taxonomy 19.8.1.2.1. By Product 19.8.1.2.2. By Application 19.8.1.2.3. By Purpose 19.8.1.2.4. By Sample Type 19.8.1.2.5. By End User 19.8.2. Japan Market Analysis 19.8.2.1. Introduction 19.8.2.2. Market Analysis and Forecast by Market Taxonomy 19.8.2.2.1. By Product 19.8.2.2.2. By Application 19.8.2.2.3. By Purpose 19.8.2.2.4. By Sample Type 19.8.2.2.5. By End User 19.8.3. South Korea Market Analysis 19.8.3.1. Introduction 19.8.3.2. Market Analysis and Forecast by Market Taxonomy 19.8.3.2.1. By Product 19.8.3.2.2. By Application 19.8.3.2.3. By Purpose 19.8.3.2.4. By Sample Type 19.8.3.2.5. By End User 20. Oceania Market Analysis 2012 to 2022 and Forecast 2023 to 2033 20.1. Introduction / Key Findings 20.2. Historical Market Size (US$ Million) and Volume (Units) Analysis, By Market Taxonomy, 2012 to 2022 20.3. Current and Future Market Size (US$ Million) Volume (Units) Analysis and Forecast By Market Taxonomy, 2023 to 2033 20.3.1. By Country 20.3.1.1. Australia 20.3.1.2. New Zealand 20.3.2. By Product 20.3.3. By Application 20.3.4. By Purpose 20.3.5. By Sample Type 20.3.6. By End User 20.4. Market Attractiveness Analysis By Region 20.4.1. By Country 20.4.2. By Product 20.4.3. By Application 20.4.4. By Purpose 20.4.5. By Sample Type 20.4.6. By End User 20.5. Market trends 20.6. Key Market Participants - Intensity Mapping 20.7. Drivers and Restraints - Impact Analysis 20.8. Country Level Analysis & Forecast 20.8.1. Australia Market Analysis 20.8.1.1. Introduction 20.8.1.2. Market Analysis and Forecast by Market Taxonomy 20.8.1.2.1. By Product 20.8.1.2.2. By Application 20.8.1.2.3. By Purpose 20.8.1.2.4. By Sample Type 20.8.1.2.5. By End User 20.8.2. New Zealand Market Analysis 20.8.2.1. Introduction 20.8.2.2. Market Analysis and Forecast by Market Taxonomy 20.8.2.2.1. By Product 20.8.2.2.2. By Application 20.8.2.2.3. By Purpose 20.8.2.2.4. By Sample Type 20.8.2.2.5. By End User 21. Middle East and Africa Market Analysis 2012 to 2022 and Forecast 2023 to 2033 21.1. Introduction / Key Findings 21.2. Historical Market Size (US$ Million) Volume (Units) Analysis, By Market Taxonomy, 2012 to 2022 21.3. Current and Future Market Size (US$ Million) Volume (Units) Analysis and Forecast By Market Taxonomy, 2023 to 2033 21.3.1. By Country 21.3.1.1. GCC Countries 21.3.1.2. Türkiye 21.3.1.3. South Africa 21.3.1.4. Northern Africa 21.3.1.5. Rest of Middle East and Africa 21.3.2. By Product 21.3.3. By Application 21.3.4. By Purpose 21.3.5. By Sample Type 21.3.6. By End User 21.4. Market Attractiveness Analysis By Region 21.4.1. By Country 21.4.2. By Product 21.4.3. By Application 21.4.4. By Purpose 21.4.5. By Sample Type 21.4.6. By End User 21.5. Market trends 21.6. Key Market Participants - Intensity Mapping 21.7. Drivers and Restraints - Impact Analysis 21.8. Country Level Analysis & Forecast 21.8.1. GCC Countries Market Analysis 21.8.1.1. Introduction 21.8.1.2. Market Analysis and Forecast by Market Taxonomy 21.8.1.2.1. By Product 21.8.1.2.2. By Application 21.8.1.2.3. By Purpose 21.8.1.2.4. By Sample Type 21.8.1.2.5. By End User 21.8.2. Türkiye Market Analysis 21.8.2.1. Introduction 21.8.2.2. Market Analysis and Forecast by Market Taxonomy 21.8.2.2.1. By Product 21.8.2.2.2. By Application 21.8.2.2.3. By Purpose 21.8.2.2.4. By Sample Type 21.8.2.2.5. By End User 21.8.3. South Africa Market Analysis 21.8.3.1. Introduction 21.8.3.2. Market Analysis and Forecast by Market Taxonomy 21.8.3.2.1. By Product 21.8.3.2.2. By Application 21.8.3.2.3. By Purpose 21.8.3.2.4. By Sample Type 21.8.3.2.5. By End User 21.8.4. Northern Africa Market Analysis 21.8.4.1. Introduction 21.8.4.2. Market Analysis and Forecast by Market Taxonomy 21.8.4.2.1. By Product 21.8.4.2.2. By Application 21.8.4.2.3. By Purpose 21.8.4.2.4. By Sample Type 21.8.4.2.5. By End User 22. Market Structure Analysis 22.1. Market Analysis by Tier of Companies 22.2. Market Share Analysis of Top Players (%) 22.3. Market Presence Analysis 22.3.1. Regional Footprint of Players 22.3.2. Product Footprint of Players 22.3.3. Channel Footprint of Players 23. Competition Analysis 23.1. Competition Dashboard 23.2. Key Development Analysis 23.3. Branding and Promotional Strategies, By Key Players 23.4. Competition Deep Dive 23.4.1. PerkinElmer Inc. 23.4.1.1. Overview 23.4.1.2. Product Portfolio 23.4.1.3. Key Financials 23.4.1.4. Sales Footprint 23.4.1.5. SWOT Analysis 23.4.1.6. Strategy Overview 23.4.1.6.1. Marketing Strategies 23.4.1.6.2. Channel Strategies 23.4.1.6.3. Product Strategies 23.4.2. Berthold Technologies GmbH & Co.KG 23.4.2.1. Overview 23.4.2.2. Product Portfolio 23.4.2.3. Key Financials 23.4.2.4. Sales Footprint 23.4.2.5. SWOT Analysis 23.4.2.6. Strategy Overview 23.4.2.6.1. Marketing Strategies 23.4.2.6.2. Channel Strategies 23.4.2.6.3. Product Strategies 23.4.3. LKB Instruments 23.4.3.1. Overview 23.4.3.2. Product Portfolio 23.4.3.3. Key Financials 23.4.3.4. Sales Footprint 23.4.3.5. SWOT Analysis 23.4.3.6. Strategy Overview 23.4.3.6.1. Marketing Strategies 23.4.3.6.2. Channel Strategies 23.4.3.6.3. Product Strategies 23.4.4. Montreal Biotech 23.4.4.1. Overview 23.4.4.2. Product Portfolio 23.4.4.3. Key Financials 23.4.4.4. Sales Footprint 23.4.4.5. SWOT Analysis 23.4.4.6. Strategy Overview 23.4.4.6.1. Marketing Strategies 23.4.4.6.2. Channel Strategies 23.4.4.6.3. Product Strategies 23.4.5. DIAsource 23.4.5.1. Overview 23.4.5.2. Product Portfolio 23.4.5.3. Key Financials 23.4.5.4. Sales Footprint 23.4.5.5. SWOT Analysis 23.4.5.6. Strategy Overview 23.4.5.6.1. Marketing Strategies 23.4.5.6.2. Channel Strategies 23.4.5.6.3. Product Strategies 23.4.6. Abbexa 23.4.6.1. Overview 23.4.6.2. Product Portfolio 23.4.6.3. Key Financials 23.4.6.4. Sales Footprint 23.4.6.5. SWOT Analysis 23.4.6.6. Strategy Overview 23.4.6.6.1. Marketing Strategies 23.4.6.6.2. Channel Strategies 23.4.6.6.3. Product Strategies 23.4.7. IBL International GmbH 23.4.7.1. Overview 23.4.7.2. Product Portfolio 23.4.7.3. Key Financials 23.4.7.4. Sales Footprint 23.4.7.5. SWOT Analysis 23.4.7.6. Strategy Overview 23.4.7.6.1. Marketing Strategies 23.4.7.6.2. Channel Strategies 23.4.7.6.3. Product Strategies 23.4.8. Creative Biolabs 23.4.8.1. Overview 23.4.8.2. Product Portfolio 23.4.8.3. Key Financials 23.4.8.4. Sales Footprint 23.4.8.5. SWOT Analysis 23.4.8.6. Strategy Overview 23.4.8.6.1. Marketing Strategies 23.4.8.6.2. Channel Strategies 23.4.8.6.3. Product Strategies 23.4.9. MP Biomedicals 23.4.9.1. Overview 23.4.9.2. Product Portfolio 23.4.9.3. Key Financials 23.4.9.4. Sales Footprint 23.4.9.5. SWOT Analysis 23.4.9.6. Strategy Overview 23.4.9.6.1. Marketing Strategies 23.4.9.6.2. Channel Strategies 23.4.9.6.3. Product Strategies 23.4.10. ALPCO 23.4.10.1. Overview 23.4.10.2. Product Portfolio 23.4.10.3. Key Financials 23.4.10.4. Sales Footprint 23.4.10.5. SWOT Analysis 23.4.10.6. Strategy Overview 23.4.10.6.1. Marketing Strategies 23.4.10.6.2. Channel Strategies 23.4.10.6.3. Product Strategies 23.4.11. Padyab Teb Co. 23.4.11.1. Overview 23.4.11.2. Product Portfolio 23.4.11.3. Key Financials 23.4.11.4. Sales Footprint 23.4.11.5. SWOT Analysis 23.4.11.6. Strategy Overview 23.4.11.6.1. Marketing Strategies 23.4.11.6.2. Channel Strategies 23.4.11.6.3. Product Strategies 23.4.12. Merck KGaA 23.4.12.1. Overview 23.4.12.2. Product Portfolio 23.4.12.3. Key Financials 23.4.12.4. Sales Footprint 23.4.12.5. SWOT Analysis 23.4.12.6. Strategy Overview 23.4.12.6.1. Marketing Strategies 23.4.12.6.2. Channel Strategies 23.4.12.6.3. Product Strategies 23.4.13. NovoLytiX GmbH 23.4.13.1. Overview 23.4.13.2. Product Portfolio 23.4.13.3. Key Financials 23.4.13.4. Sales Footprint 23.4.13.5. SWOT Analysis 23.4.13.6. Strategy Overview 23.4.13.6.1. Marketing Strategies 23.4.13.6.2. Channel Strategies 23.4.13.6.3. Product Strategies 23.4.14. Beckman Coulter, Inc. 23.4.14.1. Overview 23.4.14.2. Product Portfolio 23.4.14.3. Key Financials 23.4.14.4. Sales Footprint 23.4.14.5. SWOT Analysis 23.4.14.6. Strategy Overview 23.4.14.6.1. Marketing Strategies 23.4.14.6.2. Channel Strategies 23.4.14.6.3. Product Strategies 23.4.15. DiaSorin S.p.A. 23.4.15.1. Overview 23.4.15.2. Product Portfolio 23.4.15.3. Key Financials 23.4.15.4. Sales Footprint 23.4.15.5. SWOT Analysis 23.4.15.6. Strategy Overview 23.4.15.6.1. Marketing Strategies 23.4.15.6.2. Channel Strategies 23.4.15.6.3. Product Strategies 23.4.16. DRG INSTRUMENTS GMBH 23.4.16.1. Overview 23.4.16.2. Product Portfolio 23.4.16.3. Key Financials 23.4.16.4. Sales Footprint 23.4.16.5. SWOT Analysis 23.4.16.6. Strategy Overview 23.4.16.6.1. Marketing Strategies 23.4.16.6.2. Channel Strategies 23.4.16.6.3. Product Strategies 23.4.17. EUROIMMUN Medizinische Labordiagnostika AG 23.4.17.1. Overview 23.4.17.2. Product Portfolio 23.4.17.3. Key Financials 23.4.17.4. Sales Footprint 23.4.17.5. SWOT Analysis 23.4.17.6. Strategy Overview 23.4.17.6.1. Marketing Strategies 23.4.17.6.2. Channel Strategies 23.4.17.6.3. Product Strategies 24. Assumptions and Acronyms Used 25. Research Methodology
Explore Healthcare Insights
View Reports
Radioimmunoassay Market
